Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306214 | 0.83 | IGF1R (0.45) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL11959855 | 0.77 | TAAR1 (0.44) | TAAR1 | |
| SCHEMBL27510060 | 0.77 | TAAR1 (0.43) | TAAR1 | |
| SCHEMBL11669981 | 0.76 | TAAR1 (0.46) | LMNAKMT2ATAAR1 | |
| SCHEMBL8722410 | 0.76 | TAAR1 (0.46) | LMNAKMT2ATAAR1 | |
| SCHEMBL10571903 | 0.75 | TAAR1 (0.59) | TAAR1 | |
| SCHEMBL9760951 | 0.75 | IDO1 (0.52) | LMNAKMT2A | |
| SCHEMBL11959866 | 0.74 | TAAR1 (0.45) | TAAR1 | |
| SCHEMBL23014787 | 0.74 | RAB9A (0.51) | LMNATAAR1 | |
| SCHEMBL10574057 | 0.73 | TAAR1 (0.62) | TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915843-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSES | SMITHKLINE BEECHAM PLC (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997041098-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-11-06 | — | — | WO | disclosed |